34 results about "Benzoate derivative" patented technology

Oral care compositions having improved taste, said compositions comprising: a carrier material; from about 0.001 to about 10%, by weight of the composition, of an oral care component selected from metal salts, antimicrobial agents, bad breath reduction agents, bleaching agents, surfactants, or a combination thereof; and from about 0.0001 to about 1%, by weight of the composition, of a TRPA1 agonist selected from vanillin esters; benzoate esters; hydroxybenzoate derivatives; methoxy benzoate derivatives; hydroxybutanedioate derivatives; benzamidobenzoate derivatives; methylpropanoate derivatives; phenyl acetate derivatives; hex-3-enoate derivatives; 2-(furan-2-ylmethylsulfanyl)-3-methylpyrazine; phenylmethoxymethylbenzene; (2R)-2-azaniumyl-3-[(2R)-2-azaniumyl-3-oxido-3-oxopropyl]disulfanylpropanoate; (3E)-2-hydroxy-4,8-dimethylnona-3,7-dienal; (2R)-2-azaniumyl-3-[(2S)-2-azaniumyl-3-oxido-3-oxopropyl]disulfanylpropanoate; (3Z)-3-butylidene-2-benzofuran-1-one; 3-methyl-N-(3-methylbutyl)butan-1-imine; 2-(furan-2-ylmethyldisulfanylmethyl)furan; and combinations thereof. Uses thereof and methods of improving the taste of an oral care composition.

The invention relates to an indoleamine2,3-dioxygenase inhibitor having a structure as shown in a formula (I), as well as a preparation method and application thereof. The IDO inhibitor is (Z)-N'-hydroxyl-N-benzoate derivative, has high inhibiting activity for IDO, can be used for effectively inhibiting the IDO activity and inhibiting immunosuppression of patients, can be widely applied to treatment or prevention of cancer or tumors, virus infection, depression, neural degeneration disease, trauma, age related cataract, organ transplant rejection or autoimmune disease, and is expected to be developed into a new generation of immunosuppressors.

The present invention relates to solid catalyst components comprising titanium, magnesium, halogen and an internal electron donor compound containing at least one 1,8-naphthyl diester compound. The 1,8-naphthyl diester compounds include naphthalene-1,8-diyl dicycloalkanecarboxylate derivatives, dicycloalkenecarboxylate derivatives, 8-(cycloalkanecarbonyloxy)naphthalene-1-yl benzoate derivatives, and 8-(cycloalkenecarbonyloxy)naphthalene-1-yl benzoate derivatives. The present invention further relates to catalyst systems containing the catalyst solid components, organoaluminum compounds, and organosilicon compounds. The present invention also relates to methods of making the solid catalyst components and the catalyst systems, and methods of polymerizing or copolymerizing alpha-olefins using the catalyst systems.

The present invention relates to catalyst systems containing solid catalyst components comprising titanium, magnesium, halogen and an internal electron donor compound having at least one ether group and at least one ketone group; organoaluminum compounds and alkyl benzoate derivatives as external electron donors. The present invention also relates to methods of making the catalyst systems, and methods of polymerizing or copolymerizing alpha-olefins using the catalyst systems.

The present invention relates to solid catalyst components comprising titanium, magnesium, halogen and an internal electron donor compound containing at least one 1,8-naphthyl diester compound. The 1,8-naphthyl diester compounds include naphthalene-1,8-diyl dicycloalkanecarboxylate derivatives, dicycloalkenecarboxylate derivatives, 8-(cycloalkanecarbonyloxy)naphthalene-1-yl benzoate derivatives, and 8-(cycloalkenecarbonyloxy)naphthalene-1-yl benzoate derivatives. The present invention further relates to catalyst systems containing the catalyst solid components, organoaluminum compounds, and organosilicon compounds. The present invention also relates to methods of making the solid catalyst components and the catalyst systems, and methods of polymerizing or copolymerizing alpha-olefins using the catalyst systems.

The invention provides benzoate derivatives. A series of benzoate derivatives are synthesized through a chemical method, comprising ester compounds, (sulfur) ether compounds and amide compounds, wherein most synthesized compounds have new chemical structures, and proved through in vitro cell activity experiments, the synthesized benzoate derivatives have obvious activities similar to nerve growth factors (NGF). Proved through an in vitro animal experiment, 2,3-dyhydroxy benzoic acid tetradecyl ester which is a new synthesized compound has the effect of enhancing the memory of senile mice, thus the benzoate derivative can be applied to preparing medicaments for preventing and treating senile dementia neurodegenerative diseases, particularly to preparing medicaments for treating the neurodegenerative diseases such as the Alzheimer's diseases (AD), and the like. The invention opens up a new medical application of the benzoate derivatives, has reasonable preparation method and simple and convenient operation and provides new treatment medicaments for preventing and treating the neurodegenerative diseases such as the senile dementia, and the like.

The present invention relates to catalyst systems containing solid catalyst components comprising titanium, magnesium, halogen and a 1,8-naphthyl diaryloate internal electron donor compound; organoaluminum compounds and alkyl benzoate derivatives as external electron donors. The present invention also relates to methods of making the catalyst systems, and methods of polymerizing or copolymerizing alpha-olefins using the catalyst systems.

The invention discloses a method for synthesizing dual-esterified 3,4,5-trihydroxybenzoxy bagasse xylan benzoate. The method comprises the steps: subjecting 3,4,5-triacetyl benzoyl chloride, which isproduced through subjecting 3,4,5-trihydroxybenzoic acid to acetylation and acyl chlorination and serves as an esterifying agent, to an esterification reaction with bagasse xylan in a N,N-dimethylformamide solvent, so as to synthesize bagasse xylan 3,4,5-trihydroxy benzoate; then, carrying out a second-step esterification reaction by taking benzoic acid as an esterifying agent and triethylamine asa catalyst, and synthesizing a dual-esterified 3,4,5-trihydroxybenzoxy bagasse xylan benzoate derivative in a dichloromethane solvent. According to the method, on the basis of unique bioactivity of xylan esterified derivatives, through introducing two kinds of active groups, the product has the advantages that the bioactivity of xylan is improved, and meanwhile, the range of application of the xylan derivatives in the fields of medicine, biology, functional materials and the like is widened.

The invention provides a process for continuously producing an aminobenzoate derivative, and a synthesis system thereof. The process comprises: putting a nitrobenzoic acid derivative, ethanol and a first catalyst into an esterification reaction device, and reacting for 1-1.5 h at a temperature of 70-75 DEG C; supplementing a nitrobenzoic acid derivatives, ethanol and a first catalyst into the esterification reaction device; making the liquid in the esterification reaction device flow into a dehydration esterification kettle; heating to azeotrope the ethanol-water in the dehydration esterification kettle, evaporating the azeotrope out of the dehydration esterification kettle, collecting the azeotrope, and discharging the liquid in the dehydration esterification kettle into a middle liquid storage groove; and making the liquid in the middle liquid storage groove flow into a hydrogenation reaction device, and carrying out a hydrogenation reaction under the action of a second catalyst at areaction temperature of 100-120 DEG C to obtain the product, wherein the pressure is kept at 0.6-1 Mpa. According to the invention, the process has advantages of continuous production and the like.

The present invention relates to a polymer composition comprising a heterophasic propylene copolymer, a mineral filler and a light stabilizers comprising a fatty acid derivative and a benzoate derivative. The polymer composition according to the present invention is applicable for automotive articles whereupon the undesired effect of stickiness is reduced significantly compared to automotive articles comprising conventional light stabilizers.

The invention relates to a method for preparing a drug Roflumilast for treating the chronic obstructive pulmonary disease. The Chinese chemical name of the drug Roflumilast is 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide. According to the method, in a process route, a dihydroxyl-substituted benzoate derivative, which can be extensively obtained, is adopted as a starting raw material, so that the consumption of noble metal catalysts is avoided, the synthesis process route is shortened, and the production cost is reduced greatly; through introducing difluoromethoxy by replacing a gaseous reagent with a solid difluoromethyl etherification reagent, which is safe, efficient, cheap and readily available, side reactions are reduced, and the selectivity of the reaction is improved; and the target product is obtained efficiently through condensing carboxyl groups and amino groups.

The invention discloses an isotretinoin amido alkyl benzoate derivative, a preparation method thereof and applications thereof. The derivative has stronger inhibition and differentiation regulating effects than isotretinoin on psoriasis, acne and epithelial cell tumors including, but not limited to skin squamous epithelial cell carcinoma, stomach cancer, lung cancer, and cervical cancer; the derivative has less influence on normal tissue cells, has a certain targeting effect on inhibiting proliferating cells, and has very less side effects than isotretinoin; and the derivative has wide promising prophylaxis and treatment applications such as cornification abnormality diseases and cell abnormal proliferation including tumors, psoriasis, acne, and other cornification abnormality dermatopathy.

The invention discloses a chemical synthesis method for 2,3,4,5-tetrahydro-1H-2-benzazepin-1-one derivatives. The synthesis method of the invention includes: reacting a substituted ortho-halo benzoic acid as a raw material with an alcohol to obtain corresponding substituted acid ester; reacting with acrylonitrile to obtain a 2-(2'-cyano-alkenyl)benzoate derivative intermediate; and conducting a ring-closure reaction in the presence of alkoxide to obtain the 2,3,4,5-tetrahydro-1H-2-benzazepin-1-one derivative. The method has the advantages of fewer reaction steps and high yield.

The invention provides a 4-formaldoxime benzoate derivative preparation method. The method mainly includes steps: dissolving 4-cyanobenzoate derivatives and hydroxylamine hydrochloride into an alcohol solvent, adding an appropriate amount of alkali, and performing reflux reaction to obtain a target product 4-formaldoxime benzoate derivative. According to the method, cyano compounds are adopted to directly obtain oxime compounds through one-step reaction. The method has advantages of mild reaction conditions, simplicity in operation, low cost, high product yield, high purity and the like and is suitable for large-scale production.

The present invention provides a novel process for the preparation of alkyl (1-alkylindol-3-ylmethyl)benzoate derivatives which process comprises the steps of: (a) reacting of an alkyl (halomethyl)benzoate with excess of an indole, said indole being unsubstituted at positions 1-, 2- and 3-, under conditions promoting alkylation at the 3-position of the indole to yield a mixture comprising alkyl (indol-3-ylmethyl)benzoate and unreacted starting indole, (b) treating the mixture obtained in step (a) with base to yield a mixture, comprising the salt of (indol-3-ylmethyl)benzoic acid and the unreacted indole, (c) recovering the unreacted indole from the mixture obtained in step (b), and recycling the indole as starting material to step (a), (d) isolating the salt of (indol-3-ylmethyl)benzoic acid and / or acidifying the salt to form (indol-3-ylmethyl)benzoic acid, (e) reacting the (indol-3-ylmethyl)benzoic acid or it's salt with alkylating agent in the presence of base to form the desired alkyl (1-alkylindol-3-ylmethyl)benzoate. The above process affords also the preparation of the anti-asthmatic leukotriene antagonist zafirlukast. In such case, methyl 3-methoxy-4-(1-methyl-5-nitroindol-3-ylmethyl)benzoate [a]is formed in step (e) of the process and this compound is subsequently converted into zafirlukast by known methods.

The invention provides water-oil soluble o-(4-chloro) benzylthio-benzoate derivatives with plant growth-regulating activity and salts thereof. The derivatives are shown as a general formula (I, II), wherein X is an oxygen atom, a nitrogen atom or a sulfur atom; n is 0, 1, 2, 3, 4, 5 and so on or (CH2)n represents alkyl carrying a branched chain; Y is Cl<->, Br<->, F<->, I<->, AcO<->, acetylsalicylic acid radical, nitric acid radical, salicylic acid radical, p-toluenesulfonic acid radical, bisulfate radical or other negative ions; R<1> is alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, alkenyl of 1-6 carbon atoms, or aryl; R<2> is alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, alkenyl of 1-6 atoms, or aryl; or R<1> and R<2> are selected from the structure in the specification.

A liquid crystalline medium containing (A) compound(s) with three 1,4-linked 6-membered rings in which one of the terminal rings is a fluorinated phenyl group and (B) 4-cyano-3-fluorophenyl benzoate derivative(s). A liquid crystalline (LC) medium (I) containing compound(s) of formula (A) and compound(s) of formula (B). Ra, Rb = H, 1-12C alkyl (optionally substituted with one CN or CF3 group or at least one halogen, and optionally with CH2 group(s) replaced by -O-, -S-, cyclobutane-1,3-diyl, -CH=CH-, -Cequivalent toC-, -CO-, -COO-, -OCO- or -OCOO-), -(A)-Z1-(B)-, -Cyc-Z1-Diox- or -Diox-Z1-Cyc-; (A), (B) = rings A, B as above; Cyc = trans-1,4-cyclohexylene; Diox = 1,3-dioxan-5,2-diyl; Z1, Z2 = -CH2CH2-, -(CH2)4-, -CH2-, -(CH2)3- or a single bond; L1-L8 = H or F; Y = F, Cl, SF5, NCS, OCN, SCN or a mono- or poly-halogenated 1-5C alkyl, alkoxy, alkenyl or alkenyloxy group. Independent claims are also included for (1) (1) electro-optical LC displays containing (I) (2) (2) TN or STN LC displays with two base plates forming a cell, a nematic LC mixture with positive dielectric anisotropy (DELTAe) in the cell, electrode layers with orientation layers on the inside of the base plates, an angle of incidence of 0-30 degrees between the base plates and the long axis of the molecules on their surface and a twist angle of 22.5-600 degrees from orientation layer to orientation layer in the cell, in which the nematic LC mixture comprises (a) 15-75 wt% of an LC component A consisting of compound(s) with a DELTAe of more than +1.5, (b) 25-85 wt% of an LC component B consisting of compound(s) with a DELTAe between -1.5 and +1.5, (c) 0-20 wt% of an LC component D consisting of compound(s) with a DELTAe of below -1.5 and (d) optionally an optically active component C in amounts such that the ratio between layer thickness (plate spacing) and natural pitch of the chiral nematic LC mixture = 0.2-1.3, and in which component A contains compound(s) of formula (A) and compound(s) of formula (B)

The invention belongs to the field of medicinal chemistry, and particularly relates to 2-(isoxazole-5-yl) phenyl-3, 4-dihydroxy benzoate and a derivative thereof as well as a synthesis method and application of the 2-(isoxazole-5-yl) phenyl-3, 4-dihydroxy benzoate. 2-(isoxazole-5-yl) phenyl-3, 4-dihydroxy benzoate is designed and synthesized, and research shows that SD-0 does not affect the intracellular total beta-catenin content, and meanwhile, beta-catenin / BCL9PPI is affected, so that beta-catenin nuclear transfer is reduced, and colorectal cancer cell proliferation caused by Wnt / beta-catenin abnormal expression is inhibited; a series of 2-(isoxazole-5-yl) phenyl-3, 4-dihydroxy benzoate derivatives are synthesized, and meanwhile, the synthetic route for preparing the compound is simple, the reaction condition is mild, and post-treatment is convenient.

A compound of the general formula (I) is provided for use in the topical treatment of infection, inflammation and / or pain: wherein R1 independently represents a methylene group, an ethylene group or a straight or branched chain C3 to C6 alkylene group; R2 independently represents a hydrogen atom, a methyl group, an ethyl group or a straight or branched chain C3 to C20 alkyl group; x represents 0 or an integer from 1 to 4 and y represents 0 or an integer from 1 to 4, wherein the sum of x and y is 4; and Z represents a hydrogen atom or (HOR1)yR2xN+; compositions including the compound; use of the compound in the manufacture of a medicament; and methods of medical treatment including the topical application of the compound.

A compound of the general formula (I) is provided for use in the topical treatment of infection, inflammation and / or pain: wherein R1 independently represents a methylene group, an ethylene group or a straight or branched chain C3 to C6 alkylene group; R2 independently represents a hydrogen atom, a methyl group, an ethyl group or a straight or branched chain C3 to C20 alkyl group; x represents 0 or an integer from 1 to 4 and y represents 0 or an integer from 1 to 4, wherein the sum of x and y is 4; and Z represents a hydrogen atom or (HOR1)yR2XN+; compositions including the compound; use of the compound in the manufacture of a medicament; and methods of medical treatment including the topical application of the compound.

The present invention relates to a borneol surface-modified antimicrobial natural textile material, using a new antimicrobial strategy of surface stereochemistry, obtained by means of a natural textile material coupled to aminosiloxane and a borneol 4-aldehyde benzoate derivative, reaction conditions of a preparation process being mild, and the preparation technique being simple. The antimicrobial natural textile material is a non-release type antimicrobial textile material, and will not release bactericide to kill a microorganism, instead affecting microorganism adhesion by means of a material surface stereochemical structure, which can ensure safety of use, will not stimulate and sensitize skin, and will not harm natural skin flora; in addition, the present material has good anti-adhesion functionality for both bacteria and fungi, capable of effectively inhibiting bacterial and fungal adhesion in the long term, and the structure is stable and washable. The present antimicrobial natural textile material is a safe, stable and environmental new antimicrobial natural textile product, which may be wide used in the medical, hygiene, environmental and clothing industries.